open access

Vol 20, No 4 (2015)
Reviews
Published online: 2015-07-01
Submitted: 2014-12-31
Get Citation

Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance

José López Torrecilla, Asunción Hervás, Almudena Zapatero, Antonio Gómez Caamaño, Victor Macías, Ismael Herruzo, Xavier Maldonado, Alfonso Gómez Iturriaga, Francesc Casas, Carmen González San Segundo
DOI: 10.1016/j.rpor.2015.04.003
·
Rep Pract Oncol Radiother 2015;20(4):259-272.

open access

Vol 20, No 4 (2015)
Reviews
Published online: 2015-07-01
Submitted: 2014-12-31

Abstract

Management of patients who experience biochemical failure after radical radiotherapy with or without hormonal therapy is highly challenging. The clinician must not only choose the type of treatment, but also the timing and optimal sequence of treatment administration. When biochemical failure occurs, numerous treatment scenarios are possible, thus making it more difficult to select the optimal approach. Moreover, rapid and ongoing advances in treatment options require that physicians make decisions that could impact both survival and quality of life.

The aim of the present consensus statement, developed by the Urological Tumour Working Group (URONCOR) of the Spanish Society of Radiation Oncology (SEOR), is to provide cancer specialists with the latest, evidence-based information needed to make the best decisions for the patient under all possible treatment scenarios.

The structure of this consensus statement follows the typical development of disease progression after biochemical failure, with the most appropriate treatment recommendations given for each stage. The consensus statement is organized into three separate chapters, as follows: biochemical failure with or without local recurrence and/or metastasis; progression after salvage therapy; and treatment of castration-resistant patients.

Abstract

Management of patients who experience biochemical failure after radical radiotherapy with or without hormonal therapy is highly challenging. The clinician must not only choose the type of treatment, but also the timing and optimal sequence of treatment administration. When biochemical failure occurs, numerous treatment scenarios are possible, thus making it more difficult to select the optimal approach. Moreover, rapid and ongoing advances in treatment options require that physicians make decisions that could impact both survival and quality of life.

The aim of the present consensus statement, developed by the Urological Tumour Working Group (URONCOR) of the Spanish Society of Radiation Oncology (SEOR), is to provide cancer specialists with the latest, evidence-based information needed to make the best decisions for the patient under all possible treatment scenarios.

The structure of this consensus statement follows the typical development of disease progression after biochemical failure, with the most appropriate treatment recommendations given for each stage. The consensus statement is organized into three separate chapters, as follows: biochemical failure with or without local recurrence and/or metastasis; progression after salvage therapy; and treatment of castration-resistant patients.

Get Citation

Keywords

Prostate cancer; Radiotherapy; Hormone therapy; PSA; Biochemical failure; Castration-resistant prostate cancer

About this article
Title

Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 20, No 4 (2015)

Pages

259-272

Published online

2015-07-01

DOI

10.1016/j.rpor.2015.04.003

Bibliographic record

Rep Pract Oncol Radiother 2015;20(4):259-272.

Keywords

Prostate cancer
Radiotherapy
Hormone therapy
PSA
Biochemical failure
Castration-resistant prostate cancer

Authors

José López Torrecilla
Asunción Hervás
Almudena Zapatero
Antonio Gómez Caamaño
Victor Macías
Ismael Herruzo
Xavier Maldonado
Alfonso Gómez Iturriaga
Francesc Casas
Carmen González San Segundo

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl